Boston Scientific Corporation dropped in the first quarter after its initial 2026 guidance came in below expectations, driven by revenue growth deceleration in its electrophysiology segment. Renaissance Investment Management noted that the electrophysiology segment had contributed substantially to revenue growth in the past, and the deceleration suggests main competitor Medtronic may be gaining market share. The stock closed at $46.92 per share on June 16, 2026, with a one-month return of negative 17.20% and a 52-week loss of 53.71%. Boston Scientific reported consolidated first-quarter 2026 revenue of $5.203 billion, representing 11.6% year-over-year growth. The company had a market capitalization of $69.74 billion.
Boston Scientific Corp2026 guidance below expectations due to electrophysiology revenue deceleration, with Medtronic gaining market share.
Medtronic PLCMain competitor Medtronic is gaining market share in electrophysiology, benefiting from Boston Scientific's deceleration.